BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 29368152)

  • 1. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
    Kantor O; Sipsy LM; Yao K; James TA
    Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Boughey JC
    Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis.
    Wu S; Wang Y; Zhang N; Li J; Xu X; Shen J; Liu G
    Ann Surg Oncol; 2018 Oct; 25(11):3150-3157. PubMed ID: 30083833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
    van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
    Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?
    Barrio AV; Mamtani A; Edelweiss M; Eaton A; Stempel M; Murray MP; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3475-3480. PubMed ID: 27469123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting axillary sentinel node status in patients with primary breast cancer.
    Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
    Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
    Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
    Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
    Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.
    Park TS; Thomas SM; Rosenberger LH; Fayanju OM; Plichta JK; Blitzblau RC; Ong CT; Hyslop T; Hwang ES; Greenup RA
    Ann Surg Oncol; 2018 Oct; 25(10):3019-3029. PubMed ID: 29978365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.
    Murphy BL; L Hoskin T; Heins CDN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Sep; 24(9):2518-2525. PubMed ID: 28484921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.